Clinical studies have shown that Sirt3 (Sirtuin 3) expression declines by 40% by 65 years of age paralleling the increased incidence of hypertension and metabolic conditions further inactivate Sirt3 because of increased NADH (nicotinamide adenine dinucleotide, reduced form) and acetyl-CoA levels. Sirt3 impairment reduces the activity of a key mitochondrial antioxidant enzyme, superoxide dismutase 2 (SOD2) because of hyperacetylation.
H ypertension is a major health problem in Western societies and a risk factor for stroke, myocardial infarction, and heart failure. 1 The blood pressure (BP) of many hypertensive patients remains poorly controlled, despite treatment with multiple drugs, 2 likely because of additional mechanisms contributing to hypertension that are unaffected by current treatments. It has been suggested that oxidative stress contributes to development of hypertension and end-organ damage. 3, 4 However, antioxidant therapy has not been developed. Mitochondria are an important source of superoxide radicals (O 2
• -
), and we have previously shown that the mitochondria become dysfunctional in hypertension and have defined novel role of mitochondrial O 2
• -in this disease. 5, 6 We have found that genetic manipulation of the mitochondrial antioxidant enzyme superoxide dismutase 2 (SOD2) affects BP and have developed mitochondria-targeted therapies, such as SOD2 mimetics, that effectively lower BP. 5, 6 These data implicate mitochondrial O 2 • -in the development of hypertension; however, the potential role of SOD2 dysfunction is not completely understood.
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Acetylation represents a major post-translational regulation of SOD2 activity, and acetylation of highly conserved catalytic center SOD2 lysines 68 (K68) and 122 (K122) inhibits enzymatic activity. 7 Using mass spectroscopy and site-directed SOD2 mutagenesis, 3 independent groups have shown key role of Sirt3 (Sirtuin 3) in deacetylation of K68 and K122 which activates SOD2 likely because of electrostatic and steric hindrance effects. [8] [9] [10] [11] can be acetylated enzymatically 12 and nonenzymatically, 13 which is counteracted by mitochondrial deacetylase Sirt3. Other SOD2 acetylation sites include K53 and K89 which potentially affect SOD2 activity; 14 however, their role in Sirt3-mediated regulation of SOD2 activity has not been confirmed. NAD + (nicotinamide adenine dinucleotide, oxidized form)-dependent mitochondrial Sirt3 acts as a metabolic sensor, using intracellular metabolites, such as NAD + and acetyl-CoA, to modulate mitochondrial function to match nutrient supply. 15 Sirt3 is a class 1 sirtuin that has deacetylase activity for not only histones but also other proteins. Its mRNA is transcribed from nuclear DNA and is translated in the cytoplasm; however, the majority of Sirt3 translocates to the mitochondria. 16 The profound increase of hypertension with age is associated with decline of both mitochondrial energy metabolism- 17 and NAD + -dependent deacetylase activity. 16 Clinical data show that by 70 years of age, 70% of the population has hypertension, and Sirt3 expression declines by 40% by 65 years of age paralleling the increased incidence of hypertension. 17, 18 Furthermore, Sirtuins can be inactivated metabolically 19 or by S-glutathionylation at Cys204 in the catalytic region. 20 We have proposed that Sirt3 inactivation leads to SOD2 hyperacetylation, and this promotes vascular oxidative stress and hypertension.
Angiotensin II and inflammation contribute to decline in Sirt3 activity. 21 Interestingly, SOD2 expression is not changed with age, but the activity of Sirt3 and SOD2 are diminished 22 suggesting that SOD2 inactivation by acetylation can contribute to hypertension. Indeed, we have previously shown that SOD2 overexpression attenuates hypertension, 5 whereas SOD2 depletion enhances oxidative stress and hypertension. 23 In this work, we have investigated whether loss of Sirt3 increases vascular oxidative stress because of SOD2 hyperacetylation and this promotes hypertension.
Methods

Reagents
Dihydroethidium-and mitochondria-targeted fluorescent O2• (mito-SOX) probes were supplied by Invitrogen (Grand Island, NY). Sirt3, antiacetyl-K68-SOD2, and GSH (glutathione, reduced form) antibodies were obtained from Abcam (San Francisco, CA). The specificity of acetyl-K68-SOD2 antibodies (ab137037) was previously validated in mouse models with reduced Sirt3 expression-and site-directed mutagenesis of K68 in cells.
9,24,25 (2-[2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino]-2-oxoethyl) triphenylphosphonium (mitoTEM-PO) was purchased from Enzo Life Sciences (San Diego, CA). SOD2 antibodies were obtained from Santa Cruz Biotechnology (Dallas, TX). All other reagents were obtained from Sigma (St Louis, MO).
Cell Culture
Human aortic endothelial cells were purchased from Lonza (Chicago, IL) and cultured in EGM-2 medium supplemented with 2% FBS (fetal bovine serum) but without antibiotics. On the day before the study, the FBS concentration was reduced to 1%.
Animal Experiments
Mice lacking the Sirt3 protein (SIRT3 • -in Sirt3-deleted mice, 6 days after saline or angiotensin II minipump placement, Sirt3 −/− and C57Bl/6J mice received a second minipump for infusion of vehicle, mitochondria-targeted hydrogen peroxide scavenger ebselen (mitoEbselen; 1.5 mg/kg per day), or mitoTEMPO (1.5 mg/kg per day). mitoTEMPO was supplied in saline. mitoEbselen was dissolved in DMSO (dimethyl sulfoxide) and diluted 50% with saline. BP was monitored by the tail cuff method as described previously. 27, 28 Vanderbilt Institutional Animal Care and Use Committee approved the procedures.
Superoxide Measurements Using High-Performance Liquid Chromatography
Cells were cultured ≈80% confluence. Stock solutions of MitoSOX (4 mmol/L) and dihydroethidium (10 mmol/L) in DMSO were prepared and were diluted in KHB (Krebs/HEPES buffer) buffer to a final concentration of 2 µmol/L MitoSOX and 10 µmol/L dihydroethidium. Cells loaded with dye were incubated in a tissue culture incubator for 20 minutes. Next, buffer was aspirated, and scraped cells were mixed with methanol (300 µL) and homogenized with a glass pestle. The cell homogenate was passed through a 0.22 μm syringe filter, and methanol filtrates were analyzed by high-performance liquid chromatography according to previously published protocols. 29 Dihydroethidium and MitoSOX oxidation products, 2-hydroxyethidium and ethidium, were separated using a C-18 reverse-phase column (nucleosil, 250-4.5 mm) and a mobile phase containing 0.1% trifluoroacetic acid and an acetonitrile gradient (from 37% to 47%) at a flow rate of 0.5 mL/min. Ethidium and 2-hydroxyethidium were detected with a fluorescence detector using an emission wavelength of 580 nm and an excitation of 480 nm. Production of cytoplasmic and mitochondrial O 2
• -was measured as accumulation of 2-hydroxyethidium and mito-2-hydroxyethidium in dihydroethidium or mitSOX-supplemented samples as described previously.
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NO Measurements by Electron Spin Resonance
NO production in endothelial cells and vessels was quantified by electron spin resonance (ESR) and colloid Fe(DETC) 2 as we have described previously. 30 All ESR samples were placed in quartz Dewar (Corning, New York, NY) filled with liquid nitrogen. ESR spectra were recorded using a EMX ESR spectrometer (Bruker Biospin, Corp, Billerica, MA) and a super high Q microwave cavity. The ESR settings were as follows: field sweep, 160 Gs; microwave frequency, 9.42 GHz; microwave power, 10 mW; modulation amplitude, 3 Gs; scan time, 150 ms; time constant, 5.2 sec; and receiver gain, 60 dB (n=4 scans).
Vasodilatation Study
Isometric tension studies were performed on 2-mm mouse aortic rings dissected free of perivascular fat from C57B//6J and Sirt3 −/− mice. Studies were performed in a horizontal wire myograph (DMT, Aarhus, Denmark; models 610 and 620 mol/L) containing physiological salt solution with the composition of 118 mmol/L NaCl, 4.7 mmol/L KCl, 1.2 mmol/L MgSO 4 , 1.2 mmol/L KH 2 PO 4 , 25 mmol/L NaHCO 3 , 11 mmol/L glucose, and 1.8 mmol/L CaCl 2 . The isometric tone of each vessel was recorded using LabChart Pro v7.3.7 (AD Instruments, Australia). The aortic rings were equilibrated during a 2-hour period by heating and stretching the vessels to an optimal baseline tension of 36 mN before contracting them with 3 cycles of 60 mmol/L KCl physiological saline solution. Endothelial-dependent and independent vascular relaxation was tested after preconstriction with 1uM phenylephrine. Once the vessels reached a steady-state contraction, increasing concentrations of acetylcholine were administered, and the response to each concentration of drug was recorded.
Human Studies
Human peripheral blood mononuclear cells were obtained from patients 31 with essential hypertension (BP>140/90 mm Hg) and normotensive subjects for Western blot analysis of Sirt3 and SOD2 expression and measurements of Acetyl-SOD2 by antiacetyl K68-SOD2 antibody.
Statistics
Experiments were analyzed using the Student-Neuman-Keuls post hoc test and ANOVA. P levels <0.05 were considered significant.
Results
Sirt3 Depletion Leads to SOD2 Hyperacetylation and Exacerbate Hypertension
To test a functional role of Sirt3 in the development of hypertension, we studied Sirt3-knockout mice (Sirt3 −/− ) using an angiotensin II model of hypertension and BP monitoring by telemetry. Sirt3
−/− and wild-type C57Bl/6 littermates underwent telemetry placement for subsequent BP monitoring. Ten days later, osmotic minipumps with low-suppressor dose of angiotensin II (0.3 mg/kg per day) were implanted. 5 Infusion of wild-type C57Bl/6J mice with low dose of angiotensin II led to small increase in BP to prehypertensive level of 132 mm Hg ( Figure 1A ; night). Meanwhile, infusion of Sirt3 −/− mice with low dose of angiotensin II increased BP to severe hypertension (156 mm Hg; night) compared with wild-type littermates ( Figure 1A ).
Sirt3 depletion can lead to SOD2 inactivation because of SOD2 acetylation at K68. 9 To test a functional role of SOD2 inactivation in the development of hypertension, we have studied Sirt3
−/− and SOD2 heterozygous mice (SOD2
). Both Sirt3 −/− and SOD2 +/− mice developed severe hypertension in response to low dose of angiotensin II, whereas infusion of wild-type mice increased in BP to prehypertensive level of 130 mm Hg ( Figure 1B ). Interestingly, depletion of Sirt3 and SOD2 caused similar increase of BP in angiotensin II-infused mice. We hypothesized that Sirt3 −/− depletion impaired SOD2 activity and increased mitochondrial oxidative stress because of SOD2 hyperacetylation, which mimics SOD2 depletion. To test this hypothesis, we analyzed mitochondrial O 2
• -in aorta isolated from sham-and angiotensin II-infused Sirt3 −/− mice. Sirt3 depletion significantly increased mitochondrial O 2
• -production ( Figure 2A ). Hypertension is commonly associated with a decrease in NO bioactivity because of oxidative inactivation of this radical gas. Indeed, we found that vascular NO level is significantly decreased in hypertension, as detected by the spin trap Fe(DETC) 2 and ESR, 30 and the loss of NO was exaggerated in Sirt3 −/− mice ( Figure 2B ). We analyzed Sirt3 expression and SOD2 acetylation using specific antiacetyl K68-SOD2 antibody ( Figure 2C ). Low dose of angiotensin II reduced Sirt3 expression by 20% and increased SOD2 acetylation by 65% in wild-type mice. Sirt3 deficiency enhanced SOD2 acetylation by 3-fold compared with basal SOD2 acetylation in wild-type mice. These data demonstrate that Sirt3 is impaired in hypertensive mice (wild type) and Sirt3 deficiency enhances SOD2 hyperacetylation, increases vascular oxidative stress, reduces endothelial NO, and exaggerates hypertension.
H 2 O 2 -Mediated Sirt3 S-Glutathionylation and SOD2 Hyperacetylation in Hypertension
It has been recently reported that Sirt1 deacetylase activity is regulated by reversible S-glutathionylation at Cys204 in the catalytic region. 20 The pathophysiological significance of Sirtuins S-glutathionylation, however, has not been defined, particularly as related to Sirt3 and hypertension. Because the NAD + -dependent Sirtuins are highly homologous, we hypothesized that Sirt3 might undergo this redox modulation in a manner similar to Sirt 1. We reasoned that S-glutathionylation of Sirt3 is initiated by H 2 O 2 and that this would be reduced in transgenic mCAT mice with mitochondria-targeted expression of catalase. Indeed, incubation of human recombinant Sirt3 in the presence of H 2 O 2 and reduced glutathione caused a dosedependent inactivation of Sirt3 which was associated with Sirt3 S-glutathionylation (Online Figure IA and 1B) . Of note, incubation of Sirt3 with oxidized glutathione or H 2 O 2 without GSH did not cause Sirt3 S-glutathionylation and did not affect Sirt3 activity (Online Figure IC) .
To test the functional role of Sirt3 S-glutathionylation, we analyzed SOD2 acetylation and SOD2 activity in vessels isolated from wild-type (WT) and mCAT mice infused with angiotensin II (0.7 mg/kg per day) or saline as a vehicle. Western blot analysis showed a significant increase of SOD2 acetylation in wild-type mice in response to angiotensin II infusion, and this was abrogated in mCAT mice ( Figure 3A) . Vascular SOD2 activity was significantly reduced in angiotensin II-infused WT mice, and it was preserved in mCAT mice ( Figure 3B ), whereas SOD2 expression was not affected by angiotensin II infusion or expression of mitochondrial catalase. Angiotensin II infusion in WT mice causes robust Sirt3 S-glutathionylation in vascular and kidney mitochondria ( Figure 3C ; Online Figure ID ) but scavenging mitochondrial H 2 O 2 in mCAT mice abrogated Sirt3 S-glutathionylation.
To determine the role of Sirt3 S-glutathionylation in hypertension, we investigated BP, mitochondrial O 2
• -
, and endothelial NO in angiotensin II-infused WT and mCAT mice. We found that diminished Sirt3 S-glutathionylation was associated with reduced hypertension in mCAT mice ( Figure 4A ). Furthermore, reduced Sirt3 S-glutathionylation and diminished SOD2 acetylation in mCAT mice was accompanied with abrogation of angiotensin II-induced mitochondrial O 2
• -( Figure 4B ) and protection of endothelial NO in aorta ( Figure 4C ).
In additional in vivo studies, we identified site-specific SOD2 lysine acetylation in sham and hypertensive kidney mitochondria using tandem mass spectrometry. Mitochondrial lysates were collected in the presence of the sirtuin inhibitor, nicotinamide, and pan-inhibitor of deacetylases, trichostatin A. Proteins were resolved by SDS-PAGE, and an excised 20 to 25 kDa gel region (corresponding to molecular weight of SOD2) was digested with trypsin, acetylated peptides were enriched by immunoprecipitation with antiacetyl-lysine, and the immunoprecipitated peptides analyzed using a hybrid quadrupoleOrbitrap mass spectrometer. Acetylated lysine 68, 75, and 130 from SOD2 were identified in both sham-and angiotensin II-infused kidneys (Online Table I ). SOD2 K68 was the most abundant SOD2 acetylation site detected, and more spectra from peptides bearing SOD2 acetyl-lysine were detected in angiotensin II-infused mice compared with controls (13 spectra in control versus 19 spectra in angiotensin II-infused mice), despite the nearly equivocal number of spectra in both groups. Annotated tandem mass spectra of exemplary SOD2 peptides containing acetyl-lysine 68, 75, and 130 from angiotensin IIhypertensive kidneys is presented in Online Figures III through V. Overall, these semiquantitative experiments suggest the extent of SOD2 lysine 68 acetylation was increased in angiotensin II-infused mice. These data are in line with our antiacetyl K68-SOD2 antibody Western blot analysis implicating hyperacetylation of SOD2 K68 and perhaps K75 in hypertension.
We conducted additional quantitative experiments in unenriched samples to further address the abundance of acetylation and site occupancy for each identified acetylated lysine in enrichment experiments (Online Figure VI) . Isolated kidney mitochondria from Sirt3 −/− mice were also analyzed as a positive control. No lysine-acetylated peptides from SOD2 were identified in any sample. SOD2 coverage was 71% in sham control, 58% in angiotensin II-hypertensive kidneys, and 72% in Sirt3 −/− mice (Online Figure VIB) when analyzed in data-dependent mode. The reduced SOD2 coverage in angiotensin II-treated samples relative to control and Sirt3 −/− samples coupled with the hyperacetylation in angiotensin II-treated samples suggests an even greater relative level of SOD2 acetylation measured in acetyl-lysine enriched samples described above. To further verify these findings, we subjected the same unenriched samples to LC-MS/MS paired-reaction monitoring where peptides from SOD2 containing K68 (HHAAYVNNLNATEEKYHEALAK) and K75 (YHEALAKGDVTTQVALQPALK) and their nonacetylated peptide counterparts were specifically monitored. Again, no lysine-acetylated peptides from SOD2 were identified. These findings support previous reports that mass spec measurements of SOD2 acetyl-lysine require acetyl-lysine enrichment.
Angiotensin II and Tumor Necrosis Factor-α Cooperatively Induce SOD2 Acetylation and Mitochondrial Superoxide in Human Aortic Endothelial Cells
The above studies were performed in mice. To determine whether these findings occur in human cells, we studied human aortic endothelial cells. Angiotensin II and tumor necrosis factor-α (TNFα) are commonly encountered in hypertension, and blockade of AT1 receptor and TNFα reduces end-organ damage in many forms of experimental hypertension. 32, 33 We proposed that angiotensin II and TNFα act in concert to inactivate Sirt3 and cause SOD2 hyperacetylation, ultimately leading to endothelial oxidative stress and hypertension. Indeed, we found that angiotensin II alone did not affect SOD2 acetylation but that TNFα increased SOD2 acetylation by 2-fold and that the combination of angiotensin II+TNFα caused a synergetic increase in SOD2 acetylation ( Figure 5A ). -specific product 2-OH-Mito-E + using high-performance liquid chromatography (HPLC; B, insert). 5 • -by angiotensin II and TNFα ( Figure 5B ) that was attenuated by mitoEbselen similar to inhibition of SOD2 acetylation.
These data indicate that angiotensin II and TNFα synergistically impair Sirt3 activity, and this leads to SOD2 hyperacetylation and increases mitochondrial O 2
• -flux. We directly tested the potential role of Sirt3 in these abnormalities using Sirt3 siRNA. Western blot analysis showed reduced Sirt3 expression ( Figure 5C ), increased SOD2 acetylation ( Figure 5C ), and enhanced mitochondrial O 2
• -( Figure 5D ) by angiotensin II+TNFα and Sirt3 siRNA transfection. These data demonstrate that depletion and inactivation of Sirt3 in response to angiotensin II and TNFα caused SOD2 hyperacetylation and increased mitochondrial O 2
• -
. MitoEbselen reduced SOD2 acetylation suggesting that redox-dependent Sirt3 impairment contributes to O 2
• -overproduction and endothelial oxidative stress.
Therapeutic Potential of Targeting Redox-Sensitive Sirt3 and SOD2 After Onset of Hypertension
Our studies showed that scavenging of mitochondrial H 2 O 2 in mCAT mice improves Sirt3 function and SOD2 deacetylation reducing vascular oxidative stress and hypertension ( Figures 3  and 4) . We proposed that treatment with mitochondria-targeted H 2 O 2 scavenger mitoEbselen 34 after onset of angiotensin IIinduced hypertension will improve Sirt3 function and SOD2 deacetylation, which will be lacking in Sirt3 −/− mice. To test this hypothesis, we implanted wild-type and Sirt3 −/− mice with osmotic minipump containing mitoEbselen or vehicle after 6 days of angiotensin II infusion (0.7 mg/kg per day). 6 Treatment of hypertensive C57Bl/6J mice with mitoEbselen significantly reduced BP, but mitoEbselen was not effective in Sirt3 −/− mice ( Figure 6A ). Angiotensin II infusion increased aortic H 2 O 2 and mitoEbselen treatment substantially reduced H 2 O 2 level. 6 As we expected, mitoEbselen significantly reduced SOD2 acetylation in WT mice suggesting the improvement of Sirt3 function ( Figure 6B ). These data support the therapeutic potential of targeting Sirt3 and SOD2 acetylation to reduce hypertension.
Sirt3 expression is reduced with age by 40%, 17 and hypertension can further reduce Sirt3 expression (Figure 2 ) and cause Sirt3 redox inactivation by S-glutathionylation (Figure 4 ). This can mimic the Sirt3-depleted phenotype and limit the efficacy of Sirt3-targeted therapy with age. In these cases, we propose that targeting downstream mitochondrial O 2
• -can be beneficial in treatment of hypertension. To test this hypothesis, we studied potential antihypertensive effect of mitochondria-targeted O 2
• -scavenger mitoTEMPO in Sirt3-depleted mice (Sirt3 −/− ). We implanted WT and Sirt3 −/− mice with osmotic minipump containing mitoTEMPO or vehicle after 6 days of angiotensin II infusion (0.7 mg/kg per day). It was found that mitoTEMPO treatment of Sirt3 −/− mice after onset of angiotensin II-induced hypertension reduced BP to a similar extent as in wild-type mice and significantly improved vasodilatation ( Figure 6C and 6D) . 
Angiotensin II-Induced Hypertension Correlates With SOD2 Acetylation and Diminished SOD2 Activity
To test potential correlation between SOD2 acetylation, SOD2 activity, and hypertension, we used angiotensin II model (0.7 mg/kg per day) to induce Sirt3 impairment and SOD2 hyperacetylation in C57Bl/6J wild-type mice and compared this with hypertension-resistant mCAT mice or prone to hypertension Sirt3 −/− mice. Twelve days of angiotensin II infusion BP increased to 131 mm Hg (mCAT), 155 mm Hg (WT), and 181 mm Hg (Sirt3 −/− ), which was associated with increased SOD2 acetylation in angiotensin II-infused mice and inversely correlated with vascular SOD2 activity (Figure 7 ). To directly test whether Sirt3 reduces SOD2 acetylation and recovers SOD2 activity in hypertension, we have added recombinant Sirt3 to mitochondria isolated from aortas from wild-type sham-and angiotensin II-infused mice. It was found that treatment of aortic mitochondria lysates with recombinant Sirt3 substantially reduced SOD2 acetylation and increased SOD2 activity in sham mouse mitochondria, abolished SOD2 hyperacetylation, and rescued SOD2 activity in angiotensin II-infused mouse aortic mitochondria (Online Figure VII) . These data support the role of Sirt3 impairment and SOD2 acetylation in the development of hypertension.
SOD2 Acetylation and Sirt3 Expression in Patients With Essential Hypertension
We have tested potential Sirt3 inactivation and SOD2 hyperacetylation in human subjects with essential hypertension to verify our findings in mouse models. Western blot analysis of peripheral blood mononuclear cell fraction showed 2.6-fold increase in SOD2 acetylation and 1.4-fold decrease in Sirt3 protein level in hypertensive subjects, whereas SOD2 expression was not affected (Figure 8 ; Online Figure VIII) . These data support the pathophysiological role of Sirt3 inactivation and SOD2 hyperacetylation in human hypertension.
Discussion
This study provides the first evidence that Sirt3 depletion increases endothelial production of mitochondrial O 2
• -
, diminishes endothelial NO, and promotes hypertension. Our data show that the inflammatory cytokine TNFα and angiotensin II cooperatively induce Sirt3 impairment, increase SOD2 acetylation, and enhance mitochondrial O 2 • -in human endothelial cells. In this study, we found that Sirt3 depletion increases angiotensin II-induced hypertension, and Sitr3 S-glutathionylation contributes to Sirt3 impairment in hypertension. It was found that scavenging of mitochondrial H 2 O 2 in transgenic mCAT mice prevents Sitr3 S-glutathionylation and attenuates angiotensin II-induced hypertension. Furthermore, treatment with mitochondria-targeted H 2 O 2 scavenger mitoEbselen after the onset of hypertension improved Sirt3 deacetylase activity and reduced BP in wild-type but not in Sirt3 −/− mice. This work demonstrates that Sirt3-mediated deacetylation of SOD2 plays an important role in regulation of mitochondrial oxidative stress in hypertension, and Sirt3 depletion leads to inactivation of vascular SOD2 because of hyperacetylation (Figures 2 and 7) , which promotes development of hypertension. An analysis of BP, SOD2 acetylation and vascular SOD2 activity in angiotensin II-infused mice ( Figure 7 ) revealed that Sirt3 impairment and SOD2 acetylation have etiologic roles in hypertension and support the therapeutic potential of targeting Sirt3 in hypertension ( Figure 6 ). It is important to note that mitoEbselen reduced SOD2 acetylation and diminished hypertension in wild-type but not in Sirt3 −/− mice. In this work, we have tested whether targeting downstream mitochondrial O 2
• -with SOD2 mimetics, such as mitoTEMPO, rescues Sirt3-deficient phenotype from vascular oxidative stress and hypertension. Indeed, treatment of hypertensive Sirt3 −/− mice with mitoTEMPO reduced BP to a similar level as in wild type ( Figure 6 ). It is conceivable to have some off-target effects of Sirt3 depletion and side effects of mitochondria-targeted drugs. However, the fact that mitoEbselen did not improve vascular function in Sirt3 −/− mice but mitoTEMPO was effective in Sirt3-depleted mice supports the specific effects of mitochondria-targeted drugs in Sirt3-SOD2 pathway. This is important because diminished Sirt3 expression with age 17 and redox Sirt3 inactivation can mimic the Sirt3-knockout phenotype and limit the efficacy of Sirt3-targeted therapy.
The precise mechanisms of SOD2 acetylation and how acetylation of specific lysine residues negatively regulates SOD2 activity remain uncertain. The SOD2 active site channel is surrounded by several positively charged lysine residues influencing subunit structure, active site stability, tetrameric assembly, and recognition of a negatively charged substratesuperoxide (O 2
). 11, 35 Acetylation of these lysine residues, therefore, can cause conformational changes, steric hindrance, and loss of electrostatic guidance for O 2
• -in active center. Three independent groups showed that acetylation of K68 and K122 inhibits enzymatic activity and mutation of K68 or K122 to arginine (R) mimics deacetylation and increases SOD2 activity, whereas mutation to glutamine (Q) mimics acetylation and increases oxidative stress. 8, 9, 25 Our mass spectrometry data showed increased abundance of K68 and K75 acetylation and lack of K122 acetylation in the kidney mitochondria. Other studies have also described acetylation of SOD2 at K53, K89, and K130. 7, 14 Recently, it has been reported that several-fold SOD2 overexpression in the mouse heart resulted in acetylation of only 4 specific lysine residues at K68, K122, K130, and K202 in the heart mitochondria, and acetylation of 9 residues at K68, K75, K89, K114, K122, K130, K132, K134, and K154 in cytosolic SOD2 measured by LC-MS/MS. 10 These model-and tissue-specific differences in lysine acetylation of SOD2 support a central and multifaceted role for this enzyme in both sensing metabolic and reactive oxygen species information and relaying cellular responses. SOD2 can be acetylated independently by several distinct enzymatic 12 and nonenzymatic 13, 36 mechanisms. Furthermore, deacetylation status may depend on tissue-specific Sirt3 expression. 37 Previous publications showed highly variable acetylation levels from 0.1% to 5.5% in mitochondria, 38 and K68-SOD2 acetylation in Sirt3-depleted cells can reach ≈87%. 9 In this study, we were unable to determine the site occupancy of acetylation in the SOD2 in vivo because site-specific SOD2 lysine acetylation was only detected with the aid of antiacetyl-lysine immunoprecipitation in LC-MS experiments and by Western blot, which show only relative abundance of acetylation. We did not detect SOD2 lysine acetylation without enrichment, which may indicate the low abundance of SOD2 acetylation. However, even low acetylation stoichiometry does not necessarily preclude the importance of this modification on SOD2 function. It is conceivable that low levels of SOD2 acetylation can make impact on SOD2 function because of SOD2 unfolding, disruption of SOD2 tetramer complex, and formation of aggregated/inactive pentameric SOD2. 10 Acetylation of multiple SOD2 sites can be caused by high metabolic level of acetyl-CoA. For example, SOD2 acetylation was enhanced by SOD2 incubation with acetyl-CoA at K75 and K134. 10 Acetyl-CoA is produced by fatty acid, protein, or pyruvate metabolism, and accumulation of acetyl-CoA can be a balance of nutrient supply and metabolic activity of specific cells and tissue. 36, 37, 39 High level of Sirt3 in the heart can diminish the K68 acetylation in wild-type mice and leave only trace amounts of acetylated K122, but significant SOD2 overexpression increases substrate level for nonenzymatic acetylation of K53, K89, and K130, whereas reduced Sirt3 expression increases K68 and K122 acetylation in the heart. 10 In line with previous publications, we saw an increased immunoreactivity of acetylated K68 in Sirt3-depleted mice. 9 Furthermore, SOD2 acetylation was significantly increased in hypertensive mice and human peripheral blood mononuclear cells isolated from hypertensive subjects, which was associated with reduced expression of Sirt3 and potential redox inactivation of Sirt3. The lack of acetylated K122 in our mouse studies can be potentially because of reduced stability of this modification or tissue-specific phenomenon. Despite the discrepancies in acetylation of specific lysine residues, it is clear that Sirt3 plays a key role in SOD2 deacetylation and regulation of SOD2 activity.
Our work suggests potential Sirt3-mediated interplay between oxidative stress and metabolic conditions. NAD + -dependent mitochondrial Sirt3 acts as a metabolic sensor, using intracellular metabolites, such as NAD + and acetyl-CoA, to modulate mitochondrial function to match nutrient supply. 15 Oxidative stress can inactivate Sitr3 by S-glutathionylation (Online Figure I) leading to SOD2 inactivation and inducing mitochondrial O 2
• -( Figure 5 ). This can lead to a vicious cycle between mitochondrial dysfunction and mitochondrial oxidative stress which can be mediated by hyperacetylation of mitochondrial proteins. Indeed, our LC-MS/MS analysis of hypertensive mice shows significant increase in lysine acetylation of >30 enzymes critically involved in electron transport chain, redox processes, and ATP synthesis, such as ADP/ATP translocase 40 and ATP synthase (Online Table II) , and many of these proteins are hyperacetylated in a Sirt3-dependent manner (Online Table III ). In metabolic syndrome, hyperlipidemia, diabetes mellitus, and sedentary lifestyle Sirt3 activity is metabolically downregulated by increased Acetyl-CoA and reduced NAD + . 18, 41, 42 Recently, Titze et al 43 have found metabolic changes in response to high salt are increasing fatty acid metabolism and Acetyl-CoA production. All these metabolic conditions increase mitochondrial acetylation and risk of hypertension. 19, [44] [45] [46] [47] [48] We suggest that imbalance between mitochondrial acetylation and reduced Sirt3 activity as a potential mechanistic link between metabolic conditions and hypertension.
Multiple factors, such as aging, inflammation, and metabolic conditions, are associated with both Sirt3 impairment and increased hypertension, and this can be partially mediated by SOD2 hyperacetylation. 44 It is, therefore, interesting to speculate that SOD2 hyperacetylation can be used as an integrative marker of mitochondrial impairment, which can be beneficial as a prognostic factor in hypertension. Indeed, our animal data show positive correlation of severity of hypertension with SOD2 acetylation (Figure 7) . Furthermore, our human study supports pathophysiological role of Sirt3 inactivation and SOD2 hyperacetylation in human hypertension (Figure 8 ).
In addition to hypertension, there are many other conditions, such as heart failure, atherosclerosis, diabetes mellitus, and neurodegeneration in which mitochondrial oxidative stress seems to play a role. 49, 50 It is conceivable that Sirt3 agonists and SOD2 mimetics may have therapeutic potential by targeting mitochondrial function in these conditions.
Disclosures
None.
